An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Inclusion Criteria

• •Patients having histologically-proven solid tumors, who are refractory to standard chemotherapy;
• •Patients whom chemotherapy with an investigational agent in combination with docetaxel, or paclitaxel + carboplatin is appropriate;
• •Age ≥ 18 years old
• •Creatinine clearance according to Cockcroft-Gault formula ≥ 60 mL/min
• •A minimum of 4 weeks must have elapsed since the last treatment with other cancer therapies;
• •Potassium, calcium, magnesium and phosphorus values within the normal range Total bilirubin ≤ 6 X ULN